Lilly Launches Phase III Trial for Biased Amylin Agonist Eloralintide in Obesity; Allergan Aesthetics’ Partner Aimed Aesthetic Secures Approval for Aesthetic Botulinum Toxin
IMEIK
Developer of Biomedical Soft Tissue Repair Materials
BRL Medicine
Cell and Gene Therapy Drug Developer
Zai Lab
Innovative Global Biopharmaceutical Company
Edge Medical
Developer of Robot-Assisted Minimally Invasive Surgical Systems
BIOSUN PHARMA
Innovative Drug Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
On the road to weight loss, giant Eli Lilly is sprinting.
On January 7, according to the Clinicaltrials.gov website, Eli Lilly registered a Phase III clinical trial, ENLIGHTEN-1, for its biased Amylin drug Eloralintide intended for weight loss.
New Progress of Aimek, a Medical Beauty Giant.
On January 8, Aimeike announced that the injectable Type A botulinum toxin product, exclusively distributed and produced by South Korea's Huons BioPharma Co., Ltd., had received the "Drug Registration Certificate" issued by the National Medical Products Administration.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Insilico Medicine Receives Microsoft Azure Support for Open Source DORA
On January 8, Insilico Medicine announced the launch of DORA Community Edition – a free, self-deployable comprehensive AI engine designed for scientific research and content creation. Developed by Insilico Medicine and launched with the support of Microsoft, the DORA Community Edition aims to make cutting-edge research tools accessible to more people, promote global scientific collaboration, enhance the transparency of scientific research, and accelerate innovation in biotechnology and academia.
2) BRL Medicine Changes Leadership
On January 8, BRL Medicine officially announced that Dr. Yu Xiang will formally join BRL Medicine as the Chief Executive Officer (CEO) starting from January 1, 2026. Dr. Yu Xiang will be fully responsible for the company's strategic planning, resource allocation, and overall operational management.
3) SciClone Pharmaceuticals Obtains Exclusive Promotion Rights for Zai Lab's Ripretinib in Mainland China
On January 8, SciClone Pharmaceuticals announced that it had recently reached a collaboration with Zai Lab to obtain the exclusive promotion rights for the next-generation tyrosine kinase inhibitor (TKI) Ripretinib in mainland China. Both parties will work together to advance the commercialization of this innovative drug in the Chinese market.
/ 02 /
Capital Information
1) Edge Medical's HKEX Listing
On January 8, surgical robot company Edge Medical was listed on the Hong Kong Stock Exchange.
/ 03 /
Pharmaceutical News
1) Jinsai Bio's IM19 CAR-T Cell Injection Receives Clinical Approval
On January 8, according to the CDE official website, Jinsai Bio's IM19 CAR-T Cell Injection received clinical approval and is proposed for use in comparing with the standard second-line treatment for relapsed or refractory non-Hodgkin lymphoma.
2) BIOSUN PHARMA's OB756 Tablet Receives Clinical Approval
On January 8, according to the CDE official website, BIOSUN PHARMA's OB756 tablet received clinical approval and is proposed to initiate research for the treatment of type 1 diabetes.
3) Aimeike's exclusive distribution of injectable Type A botulinum toxin product obtains drug registration certificate
On January 8, Aimeike announced that the injectable Type A botulinum toxin product produced by South Korea's Huons BioPharma Co., Ltd., for which it holds exclusive distribution rights, has been granted the "Drug Registration Certificate" issued by the National Medical Products Administration.
/ 04 /
Overseas Pharmaceutical News
1) Lilly's Amylin-Targeted Weight Loss Enters Phase III Clinical Trial
On January 7, according to the Clinicaltrials.gov website, Eli Lilly registered a phase III clinical trial, ENLIGHTEN-1, for its biased Amylin drug Eloralintide intended for weight loss.
2) $1.2 Billion: Eli Lilly Acquires Ventyx Biosciences
On January 7, Eli Lilly announced that it had reached an acquisition agreement with Ventyx Biosciences to acquire all outstanding shares of the latter at a price of $14 per share, with a total transaction value of approximately $1.2 billion.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
